Randomised controlled trialcited by the Tayebat archivefull text checked★ key study A-INS-07 in-depth review
Long-term insulin glargine in early diabetes (ORIGIN)
Basal insulin and cardiovascular and other outcomes in dysglycemia.
Overview
ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858
Over six years insulin did not change heart attacks, strokes or cancers, but caused more low-sugar episodes and 2 kg weight difference.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Does basal insulin glargine targeting normal fasting glucose reduce CV events in dysglycaemia?
- How was the study done?
International multicentre RCT, 2x2 factorial (ORIGIN)
- How many people, animals or samples were studied?
12,537; CV risk factors plus IFG, IGT or type 2 diabetes; mean age 63.5
- What was actually found?
Neutral CV and cancer outcomes; more hypoglycaemia, slight weight gain.
- How large was the observed effect?
HR 1.02 CV; HR 1.00 cancer
- What do the results mean in everyday life?
Insulin itself did not cause heart disease or cancer in this large trial.
- What are the study's limitations?
Open-label; funded by the glargine manufacturer; early-diabetes population on moderate doses (~28 units/day for 70 kg).
- What does it say about Elawady's specific claim?
Key randomised evidence against C-INS-03, C-INS-05, C-INS-06; supports hypoglycaemia/weight side effects.
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
Safety in very high-dose, late-stage type 2 diabetes.
Scientific in-depth review
1. Full reference
- Authors
- ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S
- Journal
- N Engl J Med
- Year
- 2012
- Identifier
- PMID 22686416 DOI 10.1056/NEJMoa1203858
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
Funded by Sanofi (manufacturer of glargine), which also provided regulatory support, site monitoring and drug; a Sanofi representative sat on the steering committee that developed the protocol and wrote the manuscript; data collected and analysed independently by the Population Health Research Institute (Hamilton). Several writing-committee members report fees/grants from Sanofi-Aventis and other manufacturers.
2. Research question
Does basal insulin glargine targeting normal fasting glucose reduce CV events in dysglycaemia?
3. Study design and population
- Study design
- Randomised controlled trial – Open-label, international multicentre randomised controlled trial with 2x2 factorial design (insulin glargine vs standard care; n-3 fatty acids vs placebo), ORIGIN, NCT00069784; intention-to-treat.
- Population
People aged >=50 years with cardiovascular risk factors (59% prior CV event) plus impaired fasting glucose, impaired glucose tolerance or early type 2 diabetes (mean diabetes duration 5.4 years, median HbA1c 6.4%, BMI ~29.9); mean age 63.5, 35% female.
- Country
573 sites in 40 countries
- Period
Median follow-up 6.2 years (IQR 5.8-6.7); results published 2012.
- Sample size
12,537 randomised (glargine 6,264; standard care 6,273); primary outcome status known for 12,443 (99%); 75 persons from 3 sites excluded during the trial at regulators' request after audits.
- Inclusion and exclusion criteria
Age >=50, CV risk factors, IFG/IGT or early type 2 diabetes treated with 0-1 oral agent (details in supplement/protocol).
4. Methods and endpoints
- Exposure / intervention
Evening insulin glargine titrated at least weekly to self-measured fasting glucose <=95 mg/dL (5.3 mmol/L); median dose 0.31 U/kg at year 1 rising to 0.40 U/kg by year 6; adherence 90% at 2 years, 85% at 5 years.
- Comparator
Standard care per investigator judgement and local guidelines (by study end 11% using insulin, 60% metformin).
- Endpoints
Coprimary: (1) CV death, non-fatal MI or non-fatal stroke; (2) plus revascularisation or heart-failure hospitalisation. Others: microvascular composite, incident diabetes, all-cause mortality, cancers (adjudicated), hypoglycaemia, weight.
- Statistical methods
Cox regression stratified by factorial allocation, baseline diabetes and prior CV event; type I error partitioned (0.044 and 0.01) across coprimary outcomes; pre-specified analysis plan.
5. Actual results
- Results
Coprimary 1: 2.94 vs 2.85 per 100 person-years, HR 1.02 (95% CI 0.94-1.11; P=0.63); coprimary 2: 5.52 vs 5.28, HR 1.04 (0.97-1.11; P=0.27). All-cause mortality HR 0.98 (0.90-1.08); microvascular HR 0.97 (0.90-1.05); any cancer 476 (7.6%) vs 477 (7.6%), 1.32 vs 1.32 per 100 person-years, HR 1.00 (0.88-1.13; P=0.97); cancer death HR 0.94 (0.77-1.15); heart-failure hospitalisation HR 0.90 (0.77-1.05). Incident diabetes (n=1,456 without diabetes): after second OGTT 30% vs 35%, OR 0.80 (0.64-1.00; P=0.05). Severe hypoglycaemia 1.00 vs 0.31 per 100 person-years (359 vs 113 participants; one hypoglycaemia death in glargine group); confirmed non-severe symptomatic 9.83 vs 2.68. Median weight +1.6 kg vs -0.5 kg. HbA1c difference 0.3 percentage points at 2 years.
- Absolute risks
Coprimary 1: 2.94 vs 2.85 per 100 person-years; cancer 1.32 vs 1.32 per 100 person-years; severe hypoglycaemia 1.00 vs 0.31 per 100 person-years (about 0.7 more severe and 11 more non-severe episodes per 100 person-years).
- Authors' conclusion
Glargine targeting normal fasting glucose for >6 years had a neutral effect on CV outcomes and cancers; reduced new-onset diabetes but increased hypoglycaemia and modestly increased weight.
6. Strengths
- Large RCT with >6 years follow-up and 99% outcome ascertainment
- Large, sustained contrast in insulin exposure between groups
- Adjudicated hard CV outcomes and prospectively collected, adjudicated cancers
- Pre-specified analysis plan; independent academic data analysis; registered trial
7. Weaknesses
- Open-label design (hypoglycaemia and other patient-reported outcomes susceptible to ascertainment bias)
- Sponsor (Sanofi) funding and representation on steering committee
- Population with early dysglycaemia and modest insulin doses (~0.4 U/kg) - not representative of long-standing, high-dose insulin-treated type 2 diabetes
- Metformin used by 47% in glargine arm and 60% in standard care
- Trial extended twice (stated as without knowledge of treatment effects)
- Cancer was a secondary outcome; 6 years may be short for very long-latency effects
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- structured assessment based on the full text by a single reviewer (no formal double review)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Single-reviewer RoB 2-oriented judgement from the full text; a formal RoB 2 assessment needs two independent reviewers and the protocol/supplement. Overall unchanged (some_concerns), driven by open-label design and sponsor involvement; the hard-endpoint and cancer results are judged at low risk of bias.
| Domain | Judgement | Rationale |
|---|---|---|
| D1 randomisation process | low | Large randomised trial with closely balanced baseline characteristics; allocation details in published design paper/supplement. |
| D2 deviations from intended interventions | some concerns | Open-label; 19% of glargine group permanently discontinued and 11% of standard care used insulin by end; ITT analysis appropriate for effect of assignment. |
| D3 missing outcome data | low | Primary-outcome status known for 99%. |
| D4 measurement of the outcome | low | CV outcomes and cancers adjudicated with predefined criteria; hypoglycaemia (self-reported, open-label) at higher risk but not a primary outcome. |
| D5 selection of the reported result | low | Registered trial, published protocol and predefined statistical analysis plan; coprimary outcomes reported as specified. |
Full-text review (25 October 2026): Population, dose (0.31-0.40 U/kg), adherence, comparator insulin use, all secondary HRs (mortality 0.98, cancer death 0.94, cancer events 476 vs 477) and hypoglycaemia details added; sponsor role (Sanofi on steering committee, independent PHRI analysis) and author COI documented; RoB 2 domains added, overall unchanged (some_concerns).
9. Assessment of the statistical interpretation
Precise null results: CIs exclude CV harm larger than ~11% relative and cancer harm larger than ~13% relative over 6.2 years at moderate basal doses. Hypoglycaemia increase is real but absolute rates low.
10. Relevance to the specific claim
Key randomised evidence against C-INS-03, C-INS-05, C-INS-06; supports hypoglycaemia/weight side effects.
11. Independent contrary findings
Observational cohorts A-INS-04, A-INS-08, A-INS-10.
12. Transferability to Germany and Europe
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
13. Overall methodological judgement
High-quality, sponsor-funded open-label RCT showing that basal insulin glargine for >6 years neither increased nor decreased CV events, mortality or cancers; costs were more hypoglycaemia and ~2 kg weight difference. Directly contradicts claims that insulin itself drives atherosclerosis or glargine causes cancer, within the studied dose range and population.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | some concerns |
| Precision of results | high |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | taken out of context |
14. Open questions
Effects at high insulin doses in long-standing type 2 diabetes; cancer outcomes beyond 6 years (ORIGINALE extension).
15. Linked fact checks
- Insulin (and injected insulin) is a principal driver of atherosclerosis. – Studies contradicting or limiting the claim
- Insulin therapy in type 2 diabetes roughly doubles all-cause mortality and raises cancer, renal and cardiovascular events, with a dose-response (each extra IU/kg/day +54% mortality), compared with metformin or sulfonylureas. – Studies contradicting or limiting the claim
- Insulin glargine increases cancer risk in a dose-dependent way (and long-term use increases breast cancer). – Studies contradicting or limiting the claim
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Listed in the archive bibliography for 'insulin-injections' without its own interpretation; used as general support for the claim that insulin intensification harms.
- A. What was actually studied?
Does basal insulin glargine targeting normal fasting glucose reduce CV events in dysglycaemia?
- B. What did the authors find?
Neutral CV and cancer outcomes; more hypoglycaemia, slight weight gain.
- C. What conclusions do the authors themselves draw?
Glargine targeting normal fasting glucose for >6 years had a neutral effect on CV outcomes and cancers; reduced new-onset diabetes but increased hypoglycaemia and modestly increased weight.
- D. What does the archive derive from it?
Listed among sources on insulin harms (hypoglycaemia, weight).
- E. Is this derivation scientifically justified?
The archive bibliography includes it but the narrative omits its key finding: neutral CV and cancer effects of insulin, which contradicts the cancer and atherosclerosis claims.
- Adequacy of the interpretation (by the archive)
- taken out of context